Largest male white shark spotted off the east coast of Florida
WESTERN-NORTH ATLANTIC, Fla. (WFLA) — A record-breaking male white shark was found 45 miles off the Georgia-Florida coast, making big waves on Jan. 17.
This male shark is the largest tagged fin that the OCEARCH has seen in this part of the Atlantic.
Drone video catches Bonnethead sharks near fisherman on Pinellas County beach
He is about 14 feet long and weighs around 1,653 pounds. His new name is now 'Contender' named in honor of the Contender Boats.
On Feb. 10, Contender the shark was pinged off the coast around Cape Canaveral.
To follow Contenders journey and other tagged sharks, in the Atlantic, visit the OCEARCH shark tracker.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Post
a day ago
- New York Post
Dog's ashes among dozens to rocket into orbit this weekend
Bone voyage! A beloved dog named Franz will take his final leap this weekend — into Earth's orbit. The yellow labrador's ashes will be on board the inaugural Perseverance Flight from Texas-based Celestis Inc., which is scheduled to launch around 5:30 p.m. Sunday from Vandenberg Space Force Base in Santa Barbara, CA. 4 Franz was like a sibling to Elizabeth Moore before he died at age 13 in October 2020. Celestis, Inc Carrying a total of 166 titanium and aluminum capsules, each about a quarter to a half-inch in size and filled with DNA or cremated remains, the 23-foot-tall SpaceX Falcon 9 rocket will take two trips around Earth's low orbit at a mind-boggling 17,000 mph. The space flight will last about three hours before the rocket — still carrying its priceless payload — re-enters the atmosphere and lands in the Pacific Ocean somewhere between Alaska and Hawaii, according to Celestis CEO and co-founder Charles Chafer. A recovery ship, which was already out at sea Friday in anticipation of the launch, 'will track the incoming rocket, hopefully get a visual on it, and then go pick it up out of the ocean,' Chafer explained. 4 The Texas-based company Celestis Inc.'s inaugural Perseverance Flight will take two trips around Earth's Lower Orbit after blastoff on Sunday. The capsules will first be transported to Germany, then, within two months, distributed back to the families, who each paid a whopping $3,500 to send their loved one to the stars. While the price to send Franz on the voyage was 'a lot more' than the pooch itself, his owner, Harvin Moore, said with a laugh, it was only fitting for the 'space-fanatic' Moore family to send the pup beyond the stratosphere. 'He was the best dog, just so soft and nice and loved hugs,' recalled Moore, 60, who lives in Dripping Springs, Texas, just outside Austin. 4 The Moore family can't wait to watch their beloved pooch go galactic. Celestis, Inc Franz, who was 13 when he died in October 2020, was more like a sibling than a pet to Moore's now 26-year-old daughter, Elizabeth, and son, Quinn, 21, he said. Now, the family can't wait to watch the good boy go galactic. 'The emotional power of being with a group of people who are celebrating the life of a loved one in this way … it's amazing. It's nothing we'll ever forget,' said Moore. 'It's just pure joy.' 4 The Perseverance Flight will carry a total of 166 titanium and aluminum capsules, ranging in size from a quarter to a half-inch, filled with DNA or cremated remains. Celestis, Inc 'Many people whose ashes and DNA are flying are people that always wanted to go to space in their lifetime but were never able to do that. It also helps families move from feelings of grief to joy,' Chafer said. The cremated remains of Wesley Dreyer — an aerospace engineer who helped investigate the cause of the Space Shuttle Challenger's shocking explosion after takeoff on Jan. 28, 1986 — will also be on board the Perseverance Flight, as well as DNA from a living, 3-year-old German boy.
New York Post
2 days ago
- New York Post
Scientist tracking ‘biggest ever' great white shark Contender reveals how to escape close encounter
One of the scientists involved in tracking Contender – the biggest great white shark ever recorded by researchers in the Atlantic – has revealed how to escape a close encounter. Contender, the 14-foot beast, was tagged in the North Atlantic by OCEARCH in January – a non-profit organization that conducts research on large marine animals – 45 miles off the Florida-Georgia coast, off Jacksonville and popped up off Pamlico Sound in North Carolina earlier this month. There have been a number of other reports of shark incidents in recent days – including a nine-year-old girl nearly had her hand bitten off near Boca Grande, Florida. 4 Scientist tag the 14 foot great white shark, Contender, in the Atlantic Ocean. OCEARCH / SWNS Dr. Harley Newton, chief scientist and veterinarian for OCEARCH, from Jacksonville, Florida, has dedicated her career to studying sharks – including Contender – and educating the public. She has revealed the surprising thing you should avoid wearing when swimming in the ocean – and what do to if you do come face to face with a predator. Her advice includes avoiding dawn and dusk swims, staying close to shore, swimming with a buddy, and avoid wearing shiny objects like jewellery. And she said maintain visual contact if you spot a shark, backing away slowly while facing it. While shark attacks are rare, she stresses awareness and respect for the ocean. 'The ocean is a wild place,' Dr. Newton said. 'If you see schools of fish, particularly if they're jumping out of the water, that might be something that you want to move away from because that's going to be very attractive for sharks, and it might help you avoid an accident or an incident.' 4 Dr. Harley Newton is the chief scientist and veterinarian for OCEARCH, from Jacksonville, Florida. OCEARCH / SWNS While shark attacks are extremely rare, Dr. Newton advises that maintaining visual contact with an aggressive shark is crucial for safety. As a last resort, striking the shark's nose may deter it; however, this should only be attempted if necessary. According to Dr. Newton, bull sharks and tiger sharks are considered among the most dangerous species due to their size, strength, and habitat preferences that bring them into contact with humans. She notes that all sharks should be treated with caution and respect. Dr. Newton is passionate about correcting myths about sharks. Contrary to popular belief, sharks can get cancer, can not smell blood from miles away – the max distance the length of an Olympic-size swimming pool – and are not mindless man-eaters seeking human prey. 'They are most often looking for prey or typical prey items when there are interactions with humans,' Dr. Newton said. 'They're not out there actively looking for humans. They're looking for the typical prey that they would want to eat.' OCEARCH's tracking of Contender has also provided valuable data about great white shark migration patterns. Its movements from Florida northward along the Atlantic coast have provided researchers with unprecedented insights into the behavior of adult male sharks. 'Catching an adult male shark in January was a new data point for us,' Dr. Newton noted. 'We were really excited to catch him, tag him, sample him, and release him.' 4 OCEARCH's tracking of Contender has also provided valuable data about great white shark migration patterns. OCEARCH / SWNS This tracking effort helps scientists understand shark habitat use and identify areas where human and shark activities overlap, potentially reducing the risk of negative interactions between them. The ongoing monitoring of Contender and other sharks contributes to both conservation efforts and public safety by providing real-time data about shark movements and behavior patterns. This knowledge allows for more informed beach management decisions and helps educate the public about sharing the ocean with these apex predators. As summer approaches and more people head to beaches along the Atlantic coast, Dr. Newton emphasizes that awareness and respect for the ocean environment are key to staying safe. 'Understanding that we're entering their habitat is important,' Dr. Newton said. She added: 'Sharks play a vital role in maintaining healthy ocean ecosystems, and with some simple precautions, we can safely enjoy the water while respecting these magnificent animals that have been evolving for over 400 million years.' 4 The ongoing monitoring of Contender and other sharks contributes to both conservation efforts and public safety by providing real-time data about shark movements and behavior patterns. OCEARCH / SWNS TIPS Avoid swimming at dawn or dusk when sharks are most active and hunting Stay close to shore where you can quickly exit the water if needed Always swim with a buddy rather than venturing into the ocean alone Remove shiny jewelry or accessories that might resemble fish scales and attract sharks Be aware of your surroundings, especially schools of fish jumping out of water, which could indicate predator presence Move away from areas with fishing activity, as bait and injured fish can attract sharks Maintain visual contact if you spot a shark, backing away slowly while facing it
Yahoo
2 days ago
- Yahoo
Actuate Therapeutics Reports Positive Biomarker and Machine Learning Data from Phase 2 Elraglusib Trial in First-Line Treatment of Metastatic Pancreatic Cancer at ASCO
Phase 2 highlights robust biomarker identification and survival correlations in first-line metastatic pancreatic cancer (mPDAC) treated with elraglusib CHICAGO and FORT WORTH, Texas, June 20, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) ('Actuate' or the 'Company'), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced biomarker data from a recent poster presentation at the American Society of Clinical Oncology (ASCO) annual meeting from the Phase 2 (Actuate-1801 Part 3B) trial of elraglusib in combination with gemcitabine/nab-paclitaxel (GnP) in first-line metastatic pancreatic adenocarcinoma (mPDAC). The study demonstrated the use of machine learning and statistical models to predict overall survival (OS) based on pre-dose plasma biomarkers. The poster described an analysis of 40 cytokines, chemokines, soluble cell receptors, and growth factors (CCSGs) from plasma samples obtained prior to treatment from all patients enrolled in Actuate-1801 Part 3B. The analysis identified 7 biomarkers as uniquely significant predictors of favorable survival in the elraglusib-treated cohort, including one, CXCL2, with an inverse survival trend compared to the GnP control arm. This indicates that in patients not treated with elraglusib, high CXCL2 was unfavorable, but this trend is reversed with elraglusib treatment, highlighting the potential of elraglusib to favorably affect the immune microenvironment. Univariate analysis revealed strong predictive performance with CXCL2 emerging as a consistently reliable biomarker for survival across multiple cross-validation analyses. Elevated levels of CXCL2 and TRAIL were associated with improved OS, while lower levels of CCL3, IL-1α, IL-18, TGF-β, and TRAIL R3 were similarly linked to better survival. These signatures were combined into multivariate machine learning models that accurately predicted patients who would survive for greater than one year if treated with elraglusib and GnP. 'These results represent an important advance in our biomarker strategy,' said Daniel Schmitt, President & Chief Executive Officer of Actuate. 'They support the ability to use simple, non-invasive blood-based markers to potentially identify patients more likely to benefit from elraglusib. The pre-dose biomarker signatures identified in the 1801 Part 3B study, particularly involving high CXCL2 and low TGF-β, CCL3, and IL-18, which were all associated with a survival benefit, suggests that elraglusib may exert pleiotropic immunomodulatory effects regulating cytotoxic T cells, NK cells and cells of the myeloid lineage including macrophages and neutrophils. Crosstalk between components of the immune system support the growing body of evidence that elraglusib enhances immune response mechanisms critical to its antitumor efficacy.' 'The application of unbiased mathematical and machine learning models allowed us to pinpoint the strongest biomarker signals free from pre-conceived notions of elraglusib's mechanisms. What is so exciting about this project is that the unbiased approach aligns with prior mechanistic studies. The congruence of our clinical data analytics and the preclinical research combined with the strength of our predictive models gives us confidence that these biomarkers could be extremely beneficial in identifying the right patients at the right time,' said Taylor Weiskittel, MD, Ph.D., the lead author on this study. 'We look forward to applying this approach to guide the development of elraglusib in mPDAC as well as other advanced cancer indications in the future.' The company plans to test the identified biomarkers prospectively in future trials. Additional efforts will focus on optimizing sequential univariate combinations for patient stratification, refining multivariate machine learning models for predictive accuracy, and comparing these approaches head-to-head. About Actuate Therapeutics, Inc. Actuate is a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers. Actuate's lead investigational drug, elraglusib (a novel GSK-3β inhibitor), targets molecular pathways in cancer that are involved in promoting tumor growth and resistance to conventional cancer drugs such as chemotherapy through the inhibition of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) and DNA Damage Response (DDR). Elraglusib may also mediate anti-tumor immunity through the regulation of multiple immune checkpoints and immune cell function. For additional information, please visit the Company's website at Forward-Looking Statements This press release contains forward-looking statements about us, including our and other parties' clinical trials and development plans, and our industry. The words 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'might,' 'ongoing,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' 'would,' or the negative of these terms or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. All statements, other than statements related to present facts or current conditions or of historical facts, contained in this press release are forward-looking statements. Accordingly, these statements involve estimates, assumptions, substantial risks and uncertainties which could cause actual results to differ materially from those expressed in them, including but not limited to that preliminary and unpublished data including biomarker studies may be subject to change and further interpretation following the availability of more data or following a more comprehensive review of the data and should not be relied upon as a final analysis; clinical and preclinical drug development involves a lengthy and expensive process with uncertain timelines and outcomes, results of prior preclinical studies, early clinical trials, machine learning and predictive modeling are not necessarily predictive of future results and may not correlate with improved responses, and elraglusib may not achieve positive clinical results or favorable preclinical results or receive regulatory approval on a timely basis, if at all; that we may not successfully enroll additional patients or establish or advance plans for further development, including through conversations with the FDA or EMA and the standards such bodies may impose for such development; that elraglusib could be associated with side effects, adverse events or other properties or safety risks, which could delay or preclude regulatory approval, cause us to suspend or discontinue clinical trials or result in other negative consequences; our reliance on third parties to conduct our non-clinical studies and our clinical trials; our reliance on third-party licensors and ability to preserve and protect our intellectual property rights; that we face significant competition from other biotechnology and pharmaceutical companies; our ability to fund development activities, including because our financial condition raises substantial doubt as to our ability to continue as a going concern and we require additional capital to finance our operations beyond the second quarter of fiscal year 2025, and a failure to obtain this necessary capital in the near term on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our development programs, commercialization efforts or other operations. In addition, any forward-looking statements are qualified in their entirety by reference to the factors discussed under the heading 'Item 1A. Risk Factors' in our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 13, 2025, and our Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the SEC on May 15, 2025, and other filings with the SEC. Because the risk factors referred to above could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements made by us or on our behalf, you should not place undue reliance on any forward-looking statements. Further, any forward-looking statement speaks only as of the date on which it is made. New factors emerge from time to time, and it is not possible for us to predict which factors will arise. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Unless legally required, we do not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events. Investor Contact Mike MoyerManaging DirectorLifeSci Advisors, LLCmmoyer@ Media Contact Ignacio Guerrero-Ros, Ph.D., or David SchullRusso Partners, 717-2310 or (646) 942-5604Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
